Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
acute myeloid leukemia
consolidation chemotherapy
high dose cytarabine
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
18
08
2023
received:
11
05
2023
accepted:
19
08
2023
medline:
9
11
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
The last decade has seen advances in delivering outpatient consolidation therapy for acute myeloid leukemia (AML). The standard of care involves high-dose cytarabine or intermediate-dose cytarabine, given twice daily for three alternating days. At the London Regional Cancer Program, we have transitioned the administration of outpatient cytarabine to a once-daily regimen over six consecutive days. The outcomes of a longer duration interval of high-dose cytarabine and intermediate-dose cytarabine is currently unknown. This study aims to assess the feasibility of administering a continuous 6-day protocol of high-dose (HDAC-16) and intermediate-dose cytarabine (IDAC-16) consolidation therapy in the outpatient setting. This is a retrospective chart review to analyze AML patients treated with outpatient high-dose or intermediate-dose cytarabine consolidation therapy at the London Regional Cancer Program from January 1, 2019, through November 1, 2022. The primary objective was to determine the outcomes of the 6-day outpatient administration of once daily high-dose cytarabine or intermediate-dose cytarabine. Forty-five patients received 89 cycles of cytarabine as outpatients; males were 55.6% of the total population, with a median age of ~57 years. Our overall 2-year survival of HDAC-16 (57.1%) and IDAC-16 (83.3%) is consistent with the reported literature. There was no difference in delays, relapse rates, and nonrelapse mortality between both HDAC and IDAC groups. The 2-year relapse free survival was 57.1% for HDAC-16 and 66.7% for IDAC-16. Outpatient administration of intermediate-dose cytarabine once daily over six consecutive days results in similar overall survival and relapse rates as compared to high dose cytarabine consolidation chemotherapy. Moving to a once daily administration schedule can alleviate logistical and/or accessibility hurdles for outpatient oncology clinics. Prospective randomized trials are needed in this setting to validate our results.
Substances chimiques
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-894Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kantarjian H. Acute myeloid leukemia - major progress over four decades and glimpses into the future. Am J Hematol. 2016;91:131-145.
Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.
Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136-1152.
Zhang Y, Qian JJ, Wang L, et al. Intermediate-high dose cytarabine consolidation therapy in younger adults with acute myeloid leukemia and favorable-intermediate cytogenetic risk: a retrospective study of 124 patients in a single Chinese hospital. Zhonghua Xue Ye Xue Za Zhi. 2019;40:429-431.
Cao XX, Wang SJ, Duan MH, et al. Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2017;38:330-333.
Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:721-749.
Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062.
Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemo- therapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: cancer and leukemia group B study 9222. Blood. 2005;105(9):3420-3427.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med. 1994;331:896-903.
Li W, Gong X, Sun M, et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PloS One. 2014;9(10):e110153.
Jaramillo S, Benner A, Krauter J, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7(5):e564.
Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027-1036.
Wu D, Duan C, Chen L, Chen S. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep. 2017;7:9509.
Schaich M, Rollig C, Soucek S, et al. Cytarabine dose at 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011;29(19):2696-2702.
Wei H, Wang Y, Gale RP, et al. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res. 2020;26:3154-3161.
Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
Leunis A, Blommestein HM, Huijgens PC, Blijlevens NMA, Jongen-Lavrencic M, Uyl-de Groot CA. The costs of initial treatment for patients with acute myeloid leukemia in The Netherlands. Leuk Res. 2013;37(3):245-250.
Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30(3):237-247.
El-Jawahri AR, Traeger LN, Kuzmuk K, et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015;121(6):951-959.
Cox KM, Goel S, O'Connell RL, et al. A randomized crossover trial comparing inpatient and outpatient administration of high dose cisplatin. Intern Med J. 2011;41(2):172-178.
Halim TY, Song KW, Barnett MJ, et al. Positive impact of selective outpatient management of high-risk acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol. 1996;51(1):26-31.
Allen MR, Aljitawi OS, He J, et al. Outpatient cytarabine administration is safe and effective for consolidation in acute myeloid leukemia. Blood. 2013;122:5030.
Rodrigues ALM, do Nascimento DM, de Lima JM, et al. Safety and feasibility of outpatient high dose cytarabine for acute myeloid leukemia in the Brazilian Amazon. Int J Hematol Oncol. Stem Cell Res. 2020;14(3):151-156.
Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
Li W, Richter K, Lee J, McCarthy K, Kubal T. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2022;28(8):1812-1818.
Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: a review. Leukemia. 1988;2:253-260.
Benke S, Bow EJ, Schacter B, et al. Infectious morbidity and hospitalization requirements of patients with acute myeloid leukemia receiving intensive outpatient consolidation. Blood. 2004;104(11):4524.
Vaughn JE, Othus M, Powell MA, et al. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol. 2015;1(8):1120-1127.
Saini L, Minden MD, Schuh AC, et al. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. Am J Hematol. 2012;87(3):323-326.
Vives S, Oriol A, Piernas S, et al. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. Eur J Haematol. 2015;95(6):576-582.
Canadian GUIDELINES:Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res. 2017;7(4):30-40.